Zhang and colleagues [120] reported that complete loss of TET2 protein in endometrial carcinoma was significantly associated with shorter OS (46.74 months) compared to TET2‐positive cases (66.57 months) (HR [95% CI] = 24.189 [3.115–187.822], p < 0.01) [121] (Table 3). This evidence concerns the gene TET2 and endometrial carcinoma.